Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 596

The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.

Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology

Open access
Schaeffer, Edward M., Srinivas, Sandy, Adra, Nabil, An, Yi, Barocas, Daniel, Bitting, Rhonda, Bryce, Alan, Chapin, Brian, Cheng, Heather H., D’Amico, Anthony Victor, Desai, Neil, Dorff, Tanya, Eastham, James A., Farrington, Thomas A., Gao, Xin, Gupta, Shilpa, Guzzo, Thomas, Ippolito, Joseph E., Kuettel, Michael R., Lang, Joshua M., Lotan, Tamara, McKay, Rana R., Morgan, Todd, Netto, George, Pow-Sang, Julio M., Reiter, Robert, Roach, Mack, Robin, Tyler, Rosenfeld, Stan, Shabsigh, Ahmad, Spratt, Daniel, Teply, Benjamin A., Tward, Jonathan, Valicenti, Richard, Wong, Jessica Karen, Shead, Dorothy A., Snedeker, Jenna, Freedman-Cass, Deborah A.·2023·Journal of the National Comprehensive Cancer Network

Abstract

The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management of localized disease, post-treatment monitoring, and treatment of recurrence and advanced disease. The Guidelines sections included in this article focus on the management of metastatic castration-sensitive disease, nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC). Androgen deprivation therapy (ADT) with treatment intensification is strongly recommended for patients with metastatic castration-sensitive prostate cancer. For patients with nonmetastatic CRPC, ADT is continued with or without the addition of certain secondary hormone therapies depending on prostate-specific antigen doubling time. In the mCRPC setting, ADT is continued with the sequential addition of certain secondary hormone therapies, chemotherapies, immunotherapies, radiopharmaceuticals, and/or targeted therapies. The NCCN Prostate Cancer Panel emphasizes a shared decision-making approach in all disease settings based on patient preferences, prior treatment exposures, the presence or absence of visceral disease, symptoms, and potential side effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.6004/jnccn.2023.0050

Cites

135 of 135 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 135 references

Cited by

See all 596

Metadata

Authors
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D., Bitting, R., Bryce, A., Chapin, B., Cheng, H. H., D’Amico, A. V., Desai, N., Dorff, T., Eastham, J. A., Farrington, T. A., Gao, X., Gupta, S., Guzzo, T., Ippolito, J. E., Kuettel, M. R., Lang, J. M., Lotan, T., McKay, R. R., Morgan, T., Netto, G., Pow-Sang, J. M., Reiter, R., Roach, M., Robin, T., Rosenfeld, S., Shabsigh, A., Spratt, D., Teply, B. A., Tward, J., Valicenti, R., Wong, J. K., Shead, D. A., Snedeker, J., & Freedman-Cass, D. A.
Venue
Journal of the National Comprehensive Cancer Network
Published
2023-10
Volume
21
Issue
10
Pages
1067-1096
ISSN
  • 1540-1405 (ISSN-L)
  • 1540-1413
OpenAlex
W4387581619
Cited by
596
References
135
FWCI
94.20
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. https://app.cochat.ai/papers/10.6004/jnccn.2023.0050
The paper
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D., Bitting, R., Bryce, A., Chapin, B., Cheng, H. H., D’Amico, A. V., Desai, N., Dorff, T., Eastham, J. A., Farrington, T. A., Gao, X., Gupta, S., Guzzo, T., Ippolito, J. E., Kuettel, M. R., . . . Freedman-Cass, D. A. (2023). Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2023.0050

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.